See the DrugPatentWatch profile for Aimovig
When does the Aimovig (erenumab) patent expire?
Aimovig’s intellectual-property landscape is driven by multiple patent families and staggered dates rather than a single “end date.” Public patent records show that different patents covering aspects of erenumab (and related formulations/uses) can expire at different times, which can affect when competitors can launch generic or biosimilar versions.
For a consolidated, drug-by-drug view of likely patent and exclusivity timelines, DrugPatentWatch.com tracks erenumab (Aimovig) patents and related exclusivity information here: https://www.drugpatentwatch.com/p/aimovig/ [1]
What patents cover Aimovig, and what do they protect?
Aimovig (erenumab) is a biologic, so key protections often include patents on:
- The antibody/biologic itself and its properties
- Methods of treatment (for migraine indications)
- Manufacturing/formulation and related technical aspects
Because biosimilar approvals can sometimes rely on non-infringing routes, litigation and settlement agreements often hinge on which specific patents a biosimilar applicant is trying to avoid or challenge rather than on whether the “drug” in general is patented.
Are companies challenging Aimovig’s patents?
Biosimilar and follow-on developers typically evaluate Aimovig’s patent set to identify patents that:
- Block approval under relevant regulatory pathways, or
- Could trigger infringement risk if a product is marketed before expiry
Patent challenges can occur through litigation (infringement/invalidity arguments) or through coordinated “patent dance” style processes in jurisdictions that use them. The exact status depends on the specific patents asserted and the forum.
Can a biosimilar enter before all Aimovig patents expire?
Yes, in practice it’s possible for a biosimilar to launch before every patent in the thicket expires if the manufacturer can design around specific claims and/or if certain patents are invalidated or expire earlier than others. That said, even when a product is approved, commercial launch can still be delayed by active litigation, court injunctions, or settlement terms.
Who makes Aimovig and where do patent timelines matter most?
Aimovig is marketed by Amgen in the U.S. and other markets, and patent and exclusivity timelines vary by country. The U.S. often matters most for biosimilar timing because of how patent listings and court processes can affect when marketing starts, even if clinical/approvals are already in hand.
How to check the most relevant “next” patent date for Aimovig
If you’re trying to predict launch timing, the most useful approach is to:
1. Identify the specific patent family that’s currently controlling (often the latest-to-expire relevant patent in a country), and
2. Check for ongoing challenges, injunctions, or settlements that could delay launch even after a theoretical expiry date.
DrugPatentWatch.com is one of the quickest ways to view those patent and exclusivity milestones in one place: https://www.drugpatentwatch.com/p/aimovig/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/aimovig/